This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Researchers at the Indian Institute of Science (IISc) have found that picolinic acid, a natural compound produced by mammalian cells, can block several disease-causing viruses such as SARS-CoV-2 and influenza A viruses. The Institute is now looking for partners in pharmacompanies to pursue further clinicaldevelopment of the findings.
Pharmacompanies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research.
That was the message from ‘The New Normal: Balancing the rapid evolution of trial design with patient need’ panel at the NIHR’s ClinicalResearch Network Virtual Event on Delivering Complex and Innovative Design (CID) Studies. Thankfully, many pharmacompanies seem to be gradually improving on this. Listening to patients.
This philosophy was behind Xperiome’s recent decision to split into two different functions – Raremark, a community where patients and carers can share their experiences of living with rare diseases, and Xperiome, which leverages those insights for pharmacompanies looking to develop drugs for these conditions. About the author.
But, with a growing number of cancer treatments entering the market each year and dedicated research efforts driving innovation in the sector, there are positive signs that the industry is on the right track. Phesi’s Dr Gen Li: new approaches to clinical trials in cancer.
The Food and Drug Administration’s (FDA) draft guidance, Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Subgroups in Clinical Trials , recommends sponsors develop and submit a race and ethnicity diversity plan early in clinicaldevelopment. Community-led.
Beyond digital clinical measures, digital solutions are maturing to address major challenges facing clinicalresearch and offer enormous promise to support the key performance indicators (KPIs) for every member of our industry. Pharmacompanies with more mature digital strategies are able to focus on questions of scale.
Rothenberg did not provide any information as to what his next role may be – whether he will take over the helm of a pharmacompany or assume a role on one or more boards of directors. I have every confidence in her continued success in this new role,” Rothenberg said.
Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharmacompanies, and gives tips for companies navigating this enormous market. Dr Jay Mei has nearly 30 years of experience in clinicalresearch and development of oncology therapeutics globally.
Xtalks spoke with Maria Reyes Boceta-Muñoz, Clinical Operations Head of Development R&D at GlaxoSmithKline in Spain, Portugal & Israel, to understand the current vaccine development climate and where the sector is headed. It is affected by factors such as complacency, convenience, confidence and cultural factors.
In an effort to slow the spread of the disease and prevent a second wave, pharmacompanies around the world are continuously looking to advance new methods of treatment. This week’s round up dives into developments from companies based in Australia and the US. “The Saama Technologies, Inc. ,
With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies. He notes that it already has 21 partnerships with pharmacompanies and will aim to keep more product rights than it did in the past.
Cadavid will be responsible for the strategy, direction and execution of the company’s clinicaldevelopment programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinicaldevelopment group.
Such partnerships are mutually beneficial for all involved parties as pharmacompanies have a wealth of data, insight, and connections at their disposal, resources that can play a central role in enabling early diagnosis for the NHS and patients.
In this interview, Xtalks spoke with experts from eClinical Solutions , Katrina Rice, Chief Delivery Officer, Data Services; and Diane Lacroix, Vice President, Clinical Data Management, about clinical data management for modern day digital clinical trials. elluminate Clinical Trial Management System (CTMS) Insights.
The need to develop points in time where patient insights can inform clinicalresearch is really critical. Moreover, we embed patient centricity far beyond clinicaldevelopment. Development is just the beginning. ” It’s actually part of the process.
Priothera will use the funds to progress the clinicaldevelopment of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. Axol Bioscience – Based in the U.K.,
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
189 
Let's personalize your content